We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Green Lights Medtronic’s Next-Generation Cervical Disc System

FDA Green Lights Medtronic’s Next-Generation Cervical Disc System

July 29, 2014

Medtronic said Monday it has received FDA premarket approval to launch the Prestige LP Cervical Disc system. The device, which is indicated for the treatment of single-level cervical disc radiculopathy and/or myelopathy, is the third clinically proven artificial disc in the company’s spinal portfolio.

The Prestige LP incorporates the same ball-and-trough design as the original Prestige Cervical Disc, which allows for a range of motions, including bending and rotating, Medtronic said. However, instead of requiring bone screws to attach the disc to the vertebrae, the LP attaches via two rails that press-fit into two predrilled holes created during surgery.

The LP also is made from a titanium-ceramic material that has been shown to wear more slowly and cause less MRI-interference than the previous stainless steel composition, the devicemaker said.

The U.S. launch of the Prestige LP is projected for mid-October, Medtronic spokesman Victor Rocha told Device Daily Bulletin. The LP version has been available outside the U.S. since 2004, with over 30,000 implants in 40 countries.

The PMA was based on a large prospective multicenter clinical trial of 545 patients, 280 of whom received the Prestige LP system and 265 who underwent anterior cervical discectomy and fusion, the standard care. Results at 24 months showed the Prestige LP to be a safe and effective alternative to ACDF in patients with single-level cervical disc disease.

To qualify for the Prestige LP system, patients must have failed at least six weeks of nonoperative treatment or shown signs of nerve root/spinal cord compression during treatment. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Devices Commercial Operations Submissions and Approvals

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing